Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma or Advance Renal Cell Carcinoma

NCT07494435 is registered in ClinicalTrials.gov with Zhejiang Haichang Biotech Co., Ltd. as lead sponsor.

NCT NCT07494435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07494435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma or Advance Renal Cell Carcinoma
Lead sponsor
Zhejiang Haichang Biotech Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
September 1, 2028
Enrollment
230 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepato cellular carcinoma (hcc), renal cell cancer